Authors' reply to: Could statins be a real therapeutic option for the treatment of hepatitis C?

被引：0
|
作者：
Malaguarnera, Michele [2 ]
Vacante, Marco [1 ]
Giordano, Maria [1 ]
Malaguarnera, Mariano [1 ]
Galvano, Fabio [2 ]
Volti, Giovanni Li [2 ]
机构：
[1] Univ Catania, Dept Internal Med & Syst Dis, Catania, Italy
[2] Univ Catania, Dept Biochem Med Chem & Mol Biol, Catania, Italy
来源：
HEPATITIS MONTHLY | 2011年 / 11卷 / 07期
关键词：
Hepatitis C; NAFLD; Ribavirin; Interferon; FATTY LIVER-DISEASE; PEGYLATED INTERFERON; RIBAVIRIN; ALPHA; FLUVASTATIN; EFFICACY;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：563 / 564
页数：2
相关论文
共 50 条
  • [41] Ribavirin as a Beneficial Treatment Option for Hepatitis C Virusassociated Glomerular Disease
    Fabrizi, Fabrizio
    Cresseri, Donata
    Moroni, Gabriella
    Passerini, Patrizia
    Pallotti, Francesco
    Donato, Francesca Maria
    Lampertico, Pietro
    Messa, Piergiorgio
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2020, 31 (01) : 109 - 117
  • [42] The effect of statins on PEG-interferon/ribavirin treatment for chronic hepatitis C
    Yen, Roy D.
    Prabhu, Anoop
    Mahl, Thomas
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S217 - S217
  • [43] Treatment With Statins Reduces Liver Cancer Risk In Patients With Chronic Hepatitis C
    Nyberg, Anders H.
    Sadikova, Ekaterina
    Shi, Jiaxiao
    Cheetham, T. Craig
    Chiang, Kevin
    Younossi, Zobair M.
    Nyberg, Lisa M.
    HEPATOLOGY, 2015, 62 : 1079A - 1080A
  • [44] Letter: universal screening for hepatitis C in pregnancy, children and adolescents-authors' reply
    Indolfi, Giuseppe
    Lucenteforte, Ersilia
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (07) : 979 - 980
  • [45] Commentary: triple therapy for patients with chronic hepatitis C and advanced fibrosis? Authors' reply
    Ogawa, E.
    Furusyo, N.
    Hayashi, J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (11-12) : 1408 - 1408
  • [46] Comment on the article about hepatitis B and C prevalence in donor blood -: The authors reply
    Méndez-Sánchez, N
    Baptista-González, H
    Sánchez-Gómez, H
    Bordes-Aznar, J
    Uribe, M
    SALUD PUBLICA DE MEXICO, 2000, 42 (03): : 175 - 177
  • [47] Editorial: hepatitis C direct acting antiviral agents and the kidney-authors' reply
    Maan, R.
    Feld, J. J.
    Duarte-Rojo, A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (03) : 379 - 380
  • [48] Treatment of chronic hepatitis C by therapeutic associations.
    Brissot, P
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1997, 21 (1BIS): : S89 - S95
  • [49] Commentary: treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-virals - authors' reply
    Saxena, V.
    Monto, A.
    Terrault, N.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (12) : 1428 - 1428
  • [50] Authors' reply to letter: In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care
    Phillips, Clare
    O'Sullivan, Margaret
    Schulkind, Jasmine
    Jones, Christina J.
    Verma, Sumita
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (01) : 219 - 220
12345